ARTV Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $29,999,976.00
Insider Selling (Last 12 Months): $0.00

Artiva Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Artiva Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Artiva Biotherapeutics Share Price & Price History

Current Price: $3.91
Price Change: Price Decrease of -0.69 (-15.00%)
As of 02/7/2025 05:00 PM ET

This chart shows the closing price history over time for ARTV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Artiva Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2024Global Strategic Fund I VenbioMajor ShareholderBuy416,666$12.00$4,999,992.001,936,637View SEC Filing Icon  
7/22/2024Yong-Jun HuhDirectorBuy2,083,332$12.00$24,999,984.003,306,900View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Artiva Biotherapeutics (NASDAQ:ARTV)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARTV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Artiva Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/6/2025Charles Schwab Investment Management Inc.43,526$0.44M0.0%+8.0%0.179%Search for SEC Filing on Google Icon
1/30/2025Rhumbline Advisers12,879$0.13M0.0%-13.1%0.053%Search for SEC Filing on Google Icon
1/24/2025China Universal Asset Management Co. Ltd.5,150$52K0.0%N/A0.021%Search for SEC Filing on Google Icon
12/26/2024JPMorgan Chase & Co.10,726$0.17M0.0%N/A0.044%Search for SEC Filing on Google Icon
11/27/2024Franklin Resources Inc.520,301$7.44M0.0%N/A2.142%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC19,616$0.30M0.0%N/A0.081%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC308,930$4.77M0.0%N/A1.272%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC19,616$0.30M0.0%N/A0.081%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP194,108$2.91M0.0%N/A0.799%Search for SEC Filing on Google Icon
11/15/2024State Street Corp86,559$1.34M0.0%N/A0.356%Search for SEC Filing on Google Icon
11/15/2024Samsara BioCapital LLC291,666$4.51M0.9%N/A1.201%Search for SEC Filing on Google Icon
11/15/2024RA Capital Management L.P.9,853,302$152.23M1.8%N/A40.565%Search for SEC Filing on Google Icon
11/15/2024RTW Investments LP148,844$2.30M0.0%N/A0.613%Search for SEC Filing on Google Icon
11/14/2024Acuta Capital Partners LLC44,000$0.68M0.6%N/A0.181%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC8,733$0.14M0.0%N/A0.036%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets2,728$42K0.0%N/A0.011%Search for SEC Filing on Google Icon
11/12/2024Charles Schwab Investment Management Inc.40,293$0.62M0.0%N/A0.166%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Artiva Biotherapeutics logo
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Read More on Artiva Biotherapeutics

Today's Range

Now: $3.91
Low: $3.90
High: $4.63

50 Day Range

MA: $8.90
Low: $3.91
High: $12.75

52 Week Range

Now: $3.91
Low: $3.90
High: $17.31

Volume

89,753 shs

Average Volume

86,282 shs

Market Capitalization

$94.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Artiva Biotherapeutics?

Artiva Biotherapeutics' top insider investors include:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
Learn More about top insider investors at Artiva Biotherapeutics.

Who are the major institutional investors of Artiva Biotherapeutics?

Artiva Biotherapeutics' top institutional investors include:
  1. Charles Schwab Investment Management Inc. — 0.18%
  2. Rhumbline Advisers — 0.05%
  3. China Universal Asset Management Co. Ltd. — 0.02%
Learn More about top institutional investors of Artiva Biotherapeutics stock.

Which major investors are selling Artiva Biotherapeutics stock?

In the previous quarter, ARTV stock was sold by these institutional investors:
  1. Rhumbline Advisers

Which major investors are buying Artiva Biotherapeutics stock?

Within the last quarter, ARTV stock was acquired by institutional investors including:
  1. China Universal Asset Management Co. Ltd.
  2. Charles Schwab Investment Management Inc.
In the previous year, these company insiders have bought Artiva Biotherapeutics stock:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
Learn More investors buying Artiva Biotherapeutics stock.